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Establishing Vertex Pharmaceuticals 
Inc. (Cambridge, Massachusetts) was 
a bold move. Vertex was not based on 
the biotech model of injectable 
proteins and biology, but on the big 
drug company model of chemistry. 
Vertex wanted to make the 
chemistry rational using structural 
information, a combination that only 
Agouron Pharmaceuticals Inc. (La 
Jolla, California) had relied on thus 
far. Both Agouron and Vertex have 
had their first successes with HIV 
protease inhibitors: Agouron’s 
wracept (nelfinavir) is on the market, 
and Vertex’s Agenerase (amprenavir) 
has passed phase III trials (Figure 1). 
But, as described in the book 
‘The Billion Dollar Molecule,’ 
Vertex was founded with the promise 
that it would rationally design a 
blockbuster molecule - a nontoxic 
version of the immunosuppressant 
FK.506. The book was primarily a 
tale of how Vertex, like almost any 
start-up, lurched from one crisis to 
the next and somehow survived. In 
the end the FK.506 project was a 
failure, and the book was also an 
exhaustive chronicle of that failure. 
Vertex rescued itself with other 
drug targets, including HIV protease. 
But in a strange twist, two of the 
many projects lined up behind 
amprenavir are based on molecules 
from the original FK506 program. 
The earlv toil was worth it after all. 
Chasing the billion dollar molecule 
Rejection of an organ transplant 
means a new transplant or death, so 
trdnsplanr recipients are willing to 
put up with the side-effects of 
immunosuppressive drugs. But for 
those with autoimmune diseases such 
as rheumatoid arthritis and psoriasis, 
the level of acceptable side-effects is 
far lower. The patient population and 
possible drug revenues in this market 
are, however, far higher. This is what 
drove Vertex to improve on FK506, 
which is now marketed by Fujisawa 
Pharmaceuticals (Japan) as the 
transplant drug Prograf (tacrolimus). 
With hindsight FK506 appears to 
be a curious choice for a company 
hoping to exploit protein structure. 
Discovery of FK506’s proposed target 
- the binding protein FKBP12 - 
was not announced until after Vertex 
was founded in 1989. A crystal 
structure of FKBP12 would not be 
forthcoming until mid-1991. Until 
then, Vertex’s chemists were stuck 
doing traditional medicinal chemistry. 
What Vertex did have was a 
simple assay, as FKBP12 was found 
to help protein folding by rotating 
particular bonds between amino 
acids. Unfortunately there was no 
proof that this rotamase activity, or 
even FKBP12, was relevant to the 
clinical effects of FK506. 
As Vertex, Merck, and Stuart 
Schreiber of Harvard University made 
more FK.506 derivatives, this lack of 
proof became a more urgent concern. 
Schreiber’s FK506 derivative 506BD, 
for example, bound to FKBPlZ and 
inhibited its rotamase activity, but had 
no immunosuppressant activity. 
Schreiber’s result came out just three 
months after Vertex had convinced 
Chugai Pharmaceuticals (Japan) to 
commit $30 million to the project. 
Vertex and Merck kept going. “If 
you start from the presumption that 
rotamase is the whole story then as 
soon as you find a 506BD that sends 
up a red flag and you would drop the 
project,” says Mark Murcko, vice 
president and senior research fellow at 
Vertex. “But there was the therapeutic 
importance of the area, and there was 
already a drug [tacrolimus] that looked 
like it could be marketed. The red 
flag of 506BD simply meant the 
problem was harder than we thought.” 
Figure 1 
Amprenavir (in yellow) bound to the active site 
of HIV protease. 
The new problem was to inhibit 
the real target of FK.506, which in 
early 1991 was unknown. Again the 
structure-based design team was 
stalled. And then the second blow 
came - the target for 
immunosuppression by the 
FK506-FKBPl2 complex was the 
phosphatase calcineurin. As 
calcineurin is abundant in the brain, 
the neurological side-effects of 
FK506 were probably a result of the 
drug binding its true target, not a 
result of some unwanted interaction 
that could be designed away. 
New targets 
Luckily Vertex had secured its initial 
public offering the month before 
Schreiber announced the calcineurin 
results, so the company was 
financially on its way. And by now it 
had a back-up project, which was 
based on the HIV protease structure 
that Vertex’s Manuel Navia had 
solved when he was at Merck. The 
concept for amprenavir began with 
chemist Roger ‘rung, who brought 
ideas for several new compound 
classes to the molecular modelers. 
They settled on the 
N.N-di-substituted sulfonamides. 
A new drug application for 
amprenavir will be filed towards the 
end of 1998. L’ertex will be hoping 
for an entry like that of Agouron’s 
Viracept: first-year sales (in 1997) of 
close to $300 million. t3ut amprenavir 
faces an increasingly crowded 
market. with four HIV protease 
inhibitors already approved. 
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Murcko is confident. “There’s no 
question that the world needs better 
protease inhibitors,” he says. Whereas 
existing drugs have complicated 
dosing regimens and often show cross 
resistance, amprenavir is taken twice 
daily, with or without food, and shows 
few significant drug interactions. In 
~,itro, the major amprenavir resistance 
mutation does not confer resistance to 
other protease inhibitors. 
Using structure, any way you can 
Amprenavir originated with the 
musings of a medicinal chemist, not 
with a computer constructing a 
molecule that was the best fit for an 
active site. Vertex, it seems, is not 
purely a structure company. 
“The most important thing has 
been and always will be creativity,” 
says Murcko. “Structure helps people 
think through their ideas. It’s not so 
much about coming up with brand new 
ideas but a new form of information 
that can be integrated into a project.” 
Not that Vertex hasn’t tried the 
pure approach. “In the early 1990s 
we were interested in exploring the 
limits of de novo design,” says 
Murcko. Vertex researchers came up 
with computer programs that built 
possible drugs in an active site from 
scratch. “We could be very successful 
at generating novel ideas, but many 
of the compounds were too difficult 
to synthesize. The effort to make 
one compound was often equal to 
the effort to make hundreds of 
analogs of simpler compounds.” 
The alternative is to create a 
virtual library of chemicals, and 
narrow it down to a manageable size 
using various filters. First, a program 
discards chemicals that don’t look 
like drugs (because they have toxic 
functional groups, are too large, too 
lipophilic, or too difficult to 
synthesize). Reagents or products 
can be clustered based on structural 
similarity, and one of each group 
selected as representative for testing 
purposes. The three-dimensional 
conformations of the remaining 
compounds can then be compared to 
the structure of known inhibitors, 
and only those compounds with 
certain key structural features (such 
as two hydrogen-bond donors 
separated by 10 A) are selected. 
The chemicals are now ready for 
docking into the active site of the 
target. Those compounds that can be 
docked must then be scored for 
binding, taking into account the 
effect of entropy changes, water 
displacement, lipophilic contacts, 
hydrogen bonds, and ionic contacts. 
The winners are then synthesized 
and tested in an assay. 
All the in s&co filtering is needed 
because the final steps are computer- 
intensive. “The slow step is generating 
three-dimensional conformations for 
the ligand you want to dock,” says 
Murcko. And to get through a 
reasonable number of compounds, 
scoring functions that are already 
error-prone must take short cuts. 
Numerous groups have taken a 
stab at creating scoring functions. 
“We have implemented all of the 
public ones, and approximately six of 
our own,” says Murcko. “It works 
best with consensus scoring - you 
run all of [the scoring functions] and 
then pull out compounds that do well 
with the large majority of functions.” 
The final result is an idea, not a 
specific compound. “If you had a 
perfect scoring function you could do 
a de novo design and hand [an idea 
for] a single chemical to the chemist,” 
says Murcko. “But that’s not what we 
have. When we have a good concept, 
we’re best off making a small series 
of compounds around the idea.” 
The amount of structural 
information used in different project 
varies widely. “We are big fans of 
high-throughput screening as well,” 
says Murcko. But for a project 
designed to stop inflammation by 
targeting interleukin-1 converting 
enzyme (ICE), structure led the way. 
“The ICE lead was a designed 
compound from a crystal structure,” 
says Murcko. “It’s a clean example of 
structure-based drug design. In a 
matter of weeks after the structure 
we had the ideas that led to [the 
clinical candidate] VX-740.” 
The return of FK506 
As the FK506 project was dying, a 
remarkably similar project was rising 
in its place. Like FK506, 
mycophenolic acid (MPA) is a toxic 
natural product with 
immunosuppressant activity. But it 
differs from FK506 in being a simple 
uncompetitive inhibitor, in this case 
for the rate-limiting enzyme for de 
n~vo guanosine biosynthesis. There 
are no FKBPlZ complications here. 
Vertex solved the structure of the 
MPA-enzyme complex, and used it to 
design VX-497, a novel inhibitor 
unrelated to nucleosides, which is 
entering phase II trials. MPA is toxic 
because it gets glucuronidated and 
therefore concentrates in the bile, but 
VX-497 should not be glucuronidated. 
FK506 itself is back on the scene 
in two guises. Like many large 
lipophilic molecules, FK506 binds 
the multi-drug resistance channels 
that are responsible for pumping 
cancer drugs out of the cell. A 
compound from the FK506 program 
that blocks two types of channels is 
in phase II cancer trials. 
A move into the nervous system 
started with Solomon Snyder (Johns 
Hopkins University, Baltimore, 
Maryland), who found that FKBP12 
was highly expressed in the nervous 
system, and Bruce Gold (Oregon 
Health Sciences University, Portland, 
Oregon), who used Vertex 
compounds from the FK506 program 
to speed nerve regeneration. Snyder 
is collaborating on similar work with 
Guilford Pharmaceuticals Inc. 
(Baltimore, Maryland). 
This neurophilin project, as 
Vertex calls it, is truly reminiscent of 
the original FK506 quest. Once 
again, the therapeutic mechanism is 
unknown, and the drug development 
process is largely non-structure- 
based. But with a role for calcineurin 
in nerve regeneration ruled out, 
Vertex is hoping that the return of 
FK506 will prove to be triumphant. 
William A. Wells, Biotext Ltd 
1095 Market Street #516, San Francisco, 
CA 94103-l 628, USA; wells@biotext.com. 
